Beyond the Prescription Count: MASLD, Polypharmacy, and Moving to More Precise Deprescribing - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Rethinking Medication Burden in MASLD: Toward More Targeted Deprescribing

  • By

  • Daniella Lee

  • Alexander Chaitoff

  • November 16, 2026

Share

Objective:

The article examines the objective, findings, and clinical context described in Rethinking Medication Burden in MASLD: Toward More Targeted Deprescribing.

Approach:
  • Study design: Wang et al. analyzed a nationally representative sample of community-dwelling US adults aged 65 years or older from the 2017–2020 NHANES.
  • Measures: MASLD was identified using imaging evidence of hepatic steatosis and exam- or medication-derived cardiometabolic risk. Medication exposure was assessed by self-report and pill-bottle review.
  • Analysis: Multivariable analyses accounted for selected demographic characteristics, advanced fibrosis, and specified cardiometabolic comorbidities.
Key Findings:
  • Polypharmacy increased with age and was similar in participants with and without MASLD across most age categories.
  • Among adults aged 75 years or older, polypharmacy prevalence was higher with MASLD than without it: 60.3% versus 42.7% (p < 0.01).
  • Participants with MASLD had more cardiometabolic conditions, while cardiometabolic medication use was equivalent across most age categories.
  • In the oldest group, participants with MASLD had more antihypertensive and antidiabetic prescriptions; sedating medication use and hyperpolypharmacy did not differ.
Interpretation:

The article states that the findings do not establish whether higher medication use in older adults with MASLD represents appropriate treatment, undertreatment, or overtreatment. It calls for research linking medication-use levels to clinical outcomes and for more individualized approaches to deprescribing.

Limitations:
  • The study does not resolve whether medication use among people with MASLD is appropriate or hazardous.
  • Several cardiovascular comorbidities associated with polypharmacy and MASLD were excluded from the modeling.
  • Evidence that reducing medication counts improves clinical outcomes or patient satisfaction remains limited, according to the article.
Conclusion:

The authors describe the study as an initial step toward identifying patient groups for polypharmacy interventions and argue that further epidemiologic research and precision approaches are needed to guide deprescribing.

Sources:

Original Source(s)

Related Content